Welcome to our Fund Center

This site provides extensive information about the ranges of Edmond de Rothschild Group funds. In particular, it provides simplified access to key fund-related data (performance, net asset values, features) and their commercial or legal documents.

Please enter your country and indicate which investor category you belong to:

The identity of the managers presented in this document may change during the life of the product.

Contact

Investment objective

The objective is to grow net assets by investing in companies operating in the healthcare sector, over the recommended investment period.

View moreView less

Commentary 31/01/2018

There was a positive start to the year for the healthcare sector. US companies are currently upgrading their earnings outlook for 2018. The tax-rate cuts resulting from US tax reform mainly benefits health mutuals, which continued to gain ground at the start of the year. Several US pharmaceutical and biotechnology companies have announced the repatriation of their funds held abroad. This trend should encourage acceleration in M&A transactions. Sanofi wants to catch up its backlog on acquisitions, and made two announcements in January. It is strengthening on rare blood-related diseases with its $11.6 billion bid for Bioverativ, the US specialist in the treatment of haemophilia. Sanofi will also acquire Ablynx for 3.9 billion. Meanwhile, we are reducing our exposure to US health mutuals after their very strong run in recent months (UnitedHealth, Anthem). Instead, we have introduced CVS, a company whose valuation seems largely to be pricing in concerns at possible competition from a player like Amazon entering US drug distribution. CVS has been pursuing a vertical integration strategy with the acquisition of the insurer Aetna. This transaction should generate cost savings and, above all, offer potential for synergies with its MinuteClinic rapid-care centres in the pharmacy network. Prospects for 2018 are positive for the sector with a political environment that should stop weighing in on investor sentiment. With the exception of certain specific sub-segments, valuations are running at a significant discount against the market. Visibility on earnings growth remains strong and the pace of innovation will be sustained.

View moreView less

Change in NAV

You are about to download the historical data for a portfolio. Please note that past performance is not an indication of future performance and it may vary over time. They may be affected, for example, by changes in exchange rates

To zoom in on a specific period, move the cursors on the right and left.

Net dividends reinvested Past performance and volatility does not guarantee future performance and volatility which may change over time, and can be affected by fluctuating exchange rates. Performance data does not take into account the fees and charges received when issuing and redeeming units.

Performance A-EUR

Cumulative

Annualised

Since 01/01/2018

-3.06 %

-0.87 %

-3.06 %

-0.87 %

1 Year

-13.54 %

-1.15 %

-13.47 %

-1.15 %

3 Year

-9.45 %

6.35 %

-3.25 %

2.07 %

5 year

64.29 %

94.42 %

10.43 %

14.21 %

Since inception

1,122.14 %

–

7.92 %

–

Since 01/01/2018

1 Year

3 Year

5 year

Since inception

Cumulative

Share class (A-EUR)

Benchmark

-3.06 %

-0.87 %

-13.54 %

-1.15 %

-9.45 %

6.35 %

64.29 %

94.42 %

1,122.14 %

–

Annualised

Share class (A-EUR)

Benchmark

–

-13.47 %

-1.15 %

-3.25 %

2.07 %

10.43 %

14.21 %

7.92 %

–

*Rolling periods

Annual performance

Net dividends reinvested Past performance and volatility does not guarantee future performance and volatility which may change over time, and can be affected by fluctuating exchange rates. Performance data does not take into account the fees and charges received when issuing and redeeming units.

Statistics

Volatility

Tracking Error

Correlation coefficient

Information ratio

Sharpe ratio

Share class A-EUR

Benchmark

Share class A-EUR

Benchmark

Share class A-EUR

Benchmark

Share class A-EUR

Benchmark

Share class A-EUR

Benchmark

1 Year*

13.11 %

10.77 %

5.42 %

–

0.91 %

–

-2.16 %

–

0.62 %

–

3 Year *

15.49 %

13.55 %

5.08 %

–

0.95 %

–

-0.95 %

–

0.29 %

–

Max. drawdown

Alpha

Beta

Share class A-EUR

Benchmark

Share class A-EUR

Benchmark

Share class A-EUR

Benchmark

1 Year*

-13.37 %

–

-0.23 %

–

1.11 %

–

3 Year *

-25.22 %

–

-0.41 %

–

1.08 %

–

Max. monthly gain Since inception

18.38 %

Max. monthly loss Since inception

-19.28 %

Share class A-EUR

Benchmark

1 Year*

3 Year *

1 Year*

3 Year *

Volatility

13.11 %

15.49 %

10.77 %

13.55 %

Tracking Error

5.42 %

5.08 %

–

–

Sharpe ratio

0.62 %

0.29 %

–

–

Alpha

-0.23 %

-0.41 %

–

–

Correlation coefficient

0.91 %

0.95 %

–

–

Information ratio

-2.16 %

-0.95 %

–

–

Max. monthly loss

-19.28 %

–

Max. monthly gain

18.38 %

–

Max. drawdown

-13.37 %

-25.22 %

–

–

Beta

1.11 %

1.08 %

–

–

Past performance and volatility does not guarantee future performance and volatility which may change over time, and can be affected by fluctuating exchange rates. Performance data does not take into account the fees and charges received when issuing and redeeming units.

Fund information

Inception Date (Fund)

30/04/1985

Inception Date (Part)

30/04/1985

Legal form

SICAV

Benchmark

MSCI AC World Health Care (NR)

Currency (fund)

EUR

Currency (share class)

EUR

Distribution Policy

Accumulation

Valuation frequency

Daily

Minimum initial investment

1 Share

PEA eligible

ISIN Code

LU1160356009

AuM (fund)

347 M (EUR)

Regulatory authority

CSSF

EU Regulation

UCITS

Management company

Edmond de Rothschild Asset Management (Luxembourg)

Delegated Management Company

Edmond de Rothschild Asset Management (France)

Incorporation

Luxembourg

Representative agent

Paying agent

Maximum management fee

1,700 %

Current management fee

1.700 %

Subscription and redemption conditions

Daily before 12.30 am C.E.T. on day's net asset value

Subscription fee

3.00 % max

Redemption fee

Performance fee

15,000 %

Fund documentation

(1) The rating grades the funds on a scale from 1 to 7. This rating system is based on the average fluctuations of the net asset value over the past five years. It corresponds to the variation range of the portfolio upwards and downwards. If the net asset value is less than 5 years old, the rating is determined by other regulatory calculation methods. Historical data such as those used to calculate the rating may not be a reliable indication of the future risk profile. The current category is neither a guarantee nor an objective. Category 1 does not signify a risk-free investment.